In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]
There isn't an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI's Jennifer Bright (Executive Director) and Mark Linthicum (Director [...]
The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and needed, IVI cautions about making centralized pricing decisions based on centralized value assessments within the U.S.’s current decentralized health care [...]
Pink Sheet Senior Writer, Cathy Kelly, reports on the goals and objectives of the IVI Open-Source Value Project (OSVP), how the first iteration of the tool on rheumatoid arthritis is intended to serve different health care stakeholders, and what the next application will focus on. Kelly quotes IVI Strategic Advisory Panel Chair, Sam Nussbaum, who [...]
